Madhu Kumar
Stock Analyst at Goldman Sachs
(2.91)
# 1,671
Out of 5,064 analysts
145
Total ratings
56.86%
Success rate
20.64%
Average return
Main Sectors:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $162 → $185 | $176.93 | +4.56% | 8 | Aug 29, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $11.29 | -46.86% | 8 | Jan 26, 2024 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $9.53 | +78.38% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $1.24 | +222.58% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $212.02 | -26.89% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $65.44 | -19.01% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $8.35 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $40.45 | +80.47% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $19.61 | +619.02% | 9 | Apr 14, 2023 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $39 → $34 | $17.44 | +94.95% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $2.24 | +167.86% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $6.26 | +123.64% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $21 | $11.18 | +87.84% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $22.67 | -77.94% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $2.42 | +230.58% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $11.52 | +672.57% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $580 → $120 | $7.74 | +1,451.39% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $10 | $0.26 | +3,765.48% | 1 | Aug 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $8.21 | +935.32% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $4.69 | +731.56% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $27.81 | +104.96% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.31 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.16 | +77,486.21% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $5.68 | +252.11% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $0.45 | +21,941.00% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $40.21 | -12.96% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $13.68 | +192.40% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $38.50 | +1,209.09% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $436.38 | -47.29% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $1,125 | $13.06 | +8,514.09% | 2 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $1.18 | +3,289.83% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $31.95 | -32.71% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $50.23 | -53.22% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Aug 29, 2025
Maintains: Buy
Price Target: $162 → $185
Current: $176.93
Upside: +4.56%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $11.29
Upside: -46.86%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $9.53
Upside: +78.38%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $1.24
Upside: +222.58%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $212.02
Upside: -26.89%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $65.44
Upside: -19.01%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $8.35
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $40.45
Upside: +80.47%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $19.61
Upside: +619.02%
Syndax Pharmaceuticals
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $17.44
Upside: +94.95%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $2.24
Upside: +167.86%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $6.26
Upside: +123.64%
Nov 4, 2022
Maintains: Buy
Price Target: $24 → $21
Current: $11.18
Upside: +87.84%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $22.67
Upside: -77.94%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $2.42
Upside: +230.58%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $11.52
Upside: +672.57%
Jan 19, 2022
Downgrades: Neutral
Price Target: $580 → $120
Current: $7.74
Upside: +1,451.39%
Aug 27, 2021
Downgrades: Sell
Price Target: $10
Current: $0.26
Upside: +3,765.48%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $8.21
Upside: +935.32%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $4.69
Upside: +731.56%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $27.81
Upside: +104.96%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.31
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $1.16
Upside: +77,486.21%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $5.68
Upside: +252.11%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $0.45
Upside: +21,941.00%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $40.21
Upside: -12.96%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $13.68
Upside: +192.40%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $38.50
Upside: +1,209.09%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $436.38
Upside: -47.29%
Feb 9, 2018
Maintains: Buy
Price Target: $150 → $1,125
Current: $13.06
Upside: +8,514.09%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $1.18
Upside: +3,289.83%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $31.95
Upside: -32.71%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $50.23
Upside: -53.22%